EUVIMEDEUVIMED entdecken
Editorial

Eye Drop Quality Issues: Can the FDA See This One Through?

Lyla R White, C Michael White iD

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280241233255 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Lyla R White und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Connecticut, Storrs, CT, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Ophthalmic Solutions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Food and Drug Administration (FDA) has long suffered from a lack of resources limiting their inspection capacity. They have fallen behind on proactive surveillance inspections of foreign manufacturing sites, relying instead on for-cause inspections after a problem has been discovered. Over-the-counter (OTC) products are especially vulnerable because the FDA considers them lower priority. This issue recently made big news after improperly manufactured OTC eye drops harmed users across the country, in some cases causing blindness. To prevent future harm to Americans, it is imperative that the FDA receives enough resources to keep up with their routine inspections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationOphthalmic SolutionsUnited StatesHumansNonprescription Drugs

Stichwörter der Autor:innen

FDAcontaminationdrug qualityinspectionsophthalmic

Substanzen

Ophthalmic SolutionsNonprescription Drugs

Autor:innen und Institutionen

  • School of Pharmacy, University of Connecticut, Storrs, CT, USA.

ORCID-Profile: C Michael White

Zitieren

APA

White, L. R., & White, C. M. (2024). Eye Drop Quality Issues: Can the FDA See This One Through?. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241233255

Vancouver

White LR, White CM. Eye Drop Quality Issues: Can the FDA See This One Through?. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280241233255

BibTeX
@article{White2024,
  author = {White, Lyla R and White, C Michael},
  title = {Eye Drop Quality Issues: Can the FDA See This One Through?},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280241233255}
}
Kostenlos starten →